Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

慢性咳嗽 医学 安慰剂 耐火材料(行星科学) 双盲 敌手 内科学 随机对照试验 麻醉 受体 哮喘 替代医学 病理 天体生物学 物理
作者
Lorcan P. McGarvey,Surinder Singh Birring,Alyn H. Morice,Peter V. Dicpinigaitis,Ian Douglas Pavord,Jonathan Schelfhout,Allison Martin Nguyen,Qing Li,Anjela Tzontcheva,Beata Iskold,Stuart A Green,Carmen La Rosa,David R. Muccino,John A. Smith
出处
期刊:The Lancet [Elsevier BV]
卷期号:399 (10328): 909-923 被引量:366
标识
DOI:10.1016/s0140-6736(21)02348-5
摘要

Summary

Background

Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore aim to confirm the efficacy and safety of gefapixant in participants with refractory chronic cough and unexplained chronic cough.

Methods

COUGH-1 and COUGH-2 were both double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. COUGH-1 was done in 156 sites in 17 countries and COUGH-2 in 175 sites in 20 countries. We enrolled participants who were 18 years or older with a diagnosis of refractory chronic cough or unexplained chronic cough of 1 year duration or more. Participants were also required to have a cough severity visual analogue scale score of 40 mm or more at screening and baseline. Eligible participants were randomly allocated (1:1:1), using a computer-generated allocation schedule, to one of three treatment groups: placebo, gefapixant 15 mg twice per day, or gefapixant 45 mg twice per day. All study treatments were given orally. Participants were treated over a 12-week main study period in COUGH-1 and a 24-week main study period in COUGH-2; followed by extension periods for a total of up to 52 weeks of treatment in both trials. The primary outcome was placebo-adjusted mean change in 24-h cough frequency at 12 weeks in COUGH-1 and 24 weeks in COUGH-2. Both studies were registered with ClinicalTrials.gov, NCT03449134 (COUGH-1) and NCT03449147 (COUGH-2).

Findings

From March 14, 2018, (first participant screened) to July 26, 2019, (last participant screened) 732 patients were recruited in COUGH-1 and 1317 in COUGH-2. COUGH-1 randomly assigned and treated 730 participants (243 [33×3%] with placebo, 244 [33×4%] with gefapixant 15 mg twice per day, and 243 [33×3%] with gefapixant 45 mg twice per day); COUGH-2 randomly assigned and treated 1314 participants (435 [33×1%] with placebo, 440 [33×5%] with gefapixant 15 mg twice per day, and 439 [33×4%] with gefapixant 45 mg twice per day). Participants were mostly female (542 [74×2%] of 730 in COUGH-1 and 984 [74×9%] of 1314 in COUGH-2). The mean age was 59×0 years (SD 12×6) in COUGH-1 and 58×1 years (12×1) in COUGH-2, and the mean cough duration was 11·6 years (SD 9·5) in COUGH-1 and 11·2 years (9·8) in COUGH-2. Gefapixant 45 mg twice per day showed significant reductions in 24-h cough frequency compared with placebo at week 12 in COUGH-1 (18·5% [95% CI 32·9–0·9]; p=0·041) and at week 24 in COUGH-2 (14·6% [26·1–1·4]; p=0·031). Gefapixant 15 mg twice per day did not show a significant reduction in cough frequency versus placebo in both studies. The most common adverse events were related to taste disturbance: ageusia (36 [4·9%] of 730 in COUGH-1 and 86 [6·5%] of 1314 in COUGH-2), dysgeusia (118 [16·2%] in COUGH-1 and 277 [21·1%] in COUGH-2), hypergeusia (3 [0·4%] in COUGH-1 and 6 [0×5%] in COUGH-2), hypogeusia (19 [2·6%] in COUGH-1 and 80 [6·1%] in COUGH-2), and taste disorder (28 [3·8%] in COUGH-1 and 46 [3·5%] in COUGH-2).

Interpretation

Gefapixant 45 mg twice per day is the first treatment to show efficacy with an acceptable safety profile in phase 3 clinical trials for refractory chronic cough or unexplained chronic cough.

Funding

Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
烹全鱼宴发布了新的文献求助10
刚刚
Nuyoah完成签到,获得积分10
刚刚
1秒前
笑点低不愁完成签到,获得积分20
1秒前
qyd完成签到,获得积分20
1秒前
丘比特的应助被裕溪采纳,获得10
1秒前
2秒前
AKTAO完成签到,获得积分10
2秒前
阿白发布了新的文献求助10
2秒前
活力板凳完成签到,获得积分10
3秒前
在水一方的应助被XIYBO采纳,获得10
3秒前
我是老大的应助被寒冷鸭子采纳,获得10
3秒前
4秒前
甜美的尔柳完成签到,获得积分10
4秒前
4秒前
长风完成签到,获得积分10
4秒前
Ava的应助被xie采纳,获得10
5秒前
pandaheld完成签到,获得积分10
5秒前
Chelsea发布了新的文献求助20
6秒前
6秒前
6秒前
superchen完成签到,获得积分10
6秒前
科研通AI6.3的应助被爱笑丹云采纳,获得10
7秒前
斯文败类的应助被小杨采纳,获得10
7秒前
7秒前
hhh完成签到,获得积分10
8秒前
8秒前
爱科研的小民完成签到,获得积分10
8秒前
在望的应助被科小白采纳,获得10
8秒前
Owen的应助被务实的忆雪采纳,获得10
8秒前
风吹麦浪发布了新的文献求助10
9秒前
9秒前
风吹麦浪发布了新的文献求助10
9秒前
9秒前
wang5945发布了新的文献求助10
9秒前
10秒前
wwj完成签到,获得积分20
10秒前
howay发布了新的文献求助10
10秒前
11秒前
研友_VZG7GZ的应助被AKTAO采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181279
求助须知:如何正确求助?哪些是违规求助? 9571198
关于积分的说明 21817073
捐赠科研通 7777612
什么是DOI,文献DOI怎么找? 3433454
关于科研通互助平台的介绍 2557692
邀请新用户注册赠送积分活动 2479519